All In Biotech

Drug Trial Radar · NCT02386358

Etiologic Treatment With Benznidazole in Adult Patients With Chronic Chagas Disease. A Randomized Clinical Trial

Etiologic Treatment With Benznidazole in Adult Patients With Chronic Chagas Disease. A Randomized Double Blind Clinical Trial

Last checked: Nov 20, 2026Latest source record: Mar 11, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 910 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

910

Actual

Start

Mar 1999

Primary completion

Dec 2012

Study completion Apr 2013

Sponsor

Sponsor type
Government (non-federal)
Collaborators
National Council of Scientific and Technical Research, Argentina; Pan American Health Organization; Becas Carrillo Oñativia, Ministerio de Salud, Argentina; Drugs for Neglected Diseases
First posted
Mar 11, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 20 years, up to 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is: 1. -to determine whether benznidazole (BZN) will be able to modify the natural evolution of chronic Chagas disease in adult patients by means of a randomized, double-blind clinical trial (RCT). Also: 2. -to validate therapeutic efficacy with new methods, such as recombinant antigen F29 of Trypanosoma cruzi visualized by conventional ELISA, in the context of the RCT compared with conventional serology (CS) 3. -to develop the real-time polymerase chain-reaction (RT-PCR) to quantify the parasite load as an early therapeutic effect. 4. to determine the potential of such serological and parasitological methods as predictors of therapeutic effect or failure.

Conditions

  • Chagas Disease

Interventions

  • BenznidazoleDrug

    Benznidazole at a dose 5 mg/Kg/day until 60 days have been completed or development of non-acceptable toxicity-

  • PlaceboDrug

    Placebo at a dose 5 m/Kg/day until 60 days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cardiovascular MortalityTime frame: Time to event: from date of randomization until the date of first documented progression or date of death from any cause up to 10 years of follow-up
  2. Development of heart failureTime frame: Time to event: from date of randomization until the date of first documented progression of heart failure up to 10 years of follow-up
  3. Severe arrhythmias with hemodynamic compromise or pacemaker implant or Implantable cardiac defibrillatorTime frame: Time to event: from date of randomization until the date of first documented progression up to 10 years of follow-up

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Instituto Nacional de Parasitología Dr Mario Fatala Chaben

    Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.